Health CarePharmaceuticals & Biotechnology
  • Price (DKK)500.40
  • Today's Change4.40 / 0.89%
  • Shares traded307.46k
  • 1 Year change+33.30%
  • Beta0.7329
Data delayed at least 15 minutes, as of Aug 04 2021 15:59 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Key statistics

Novozymes A/S (NZYM B:CPH) set a new 52-week high during today's trading session when it reached 501.60. Over this period, the share price is up 32.80%.
52-week range
334.60Dec 11 2020501.60Aug 04 2021
Markit short selling activity
Previous close496.00
Average volume264.50k
Shares outstanding228.26m
Free float155.11m
P/E (TTM)48.20
Market cap113.22bn DKK
EPS (TTM)10.29
Annual div (ADY)5.25
Annual div yield (ADY)1.06%
Div ex-dateMar 12 2021
Div pay-dateMar 16 2021
Data delayed at least 15 minutes, as of Aug 04 2021 15:59 BST.
More ▼
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.